Cancer

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

    - Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing…

4 months ago

Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001

CRANBERRY TOWNSHIP, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Jabez Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to ushering in…

4 months ago

Onco-Innovations Announces 90% of $0.60 Warrants Have Been Exercised

VANCOUVER, BC / ACCESS Newswire / August 15, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")…

4 months ago

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287,…

4 months ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive…

4 months ago

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi®…

4 months ago

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

– Live video webcast on Thursday, August 21st at 2:20 PM ET THE WOODLANDS, TX, Aug. 15, 2025 (GLOBE NEWSWIRE)…

4 months ago

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight…

4 months ago

Ultima Genomics’ ppmSeq™ Delivers Unmatched Combination of Sensitivity and Efficiency for Whole-Genome MRD Detection

New bioRxiv paper showcases: Tumor-informed ctDNA detection down to one-in-ten million (10-7), which extends well beyond the limits of currently…

4 months ago

Base Molecular Resonance™ Technologies Names Bryan Adams as Chief Marketing Officer

Executive Strategist to Lead Global Brand, Market Growth, and Cross-Vertical Commercialization for Quantum Detection Pioneer STUART, Fla., Aug. 14, 2025…

4 months ago